英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
tokenish查看　tokenish　在百度字典中的解释百度英翻中〔查看〕
tokenish查看　tokenish　在Google字典中的解释Google英翻中〔查看〕
tokenish查看　tokenish　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home - PolyActiva
    on providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life for patients suffering from ophthalmic diseases such as glaucoma
  • Team - PolyActiva
    Vanessa is an executive manager with 20 years’ experience in commercialization of pharmaceuticals, biological products, and medical devices Vanessa joined PolyActiva in 2017 as Head of Commercial Operations and Business Development and was appointed CEO in August 2022
  • About - PolyActiva
    PolyActiva is an innovative clinical-stage ophthalmology company with a unique proprietary polymeric prodrug technology that enables site-specific, precise and controlled drug delivery to the eye
  • PolyActiva’s PA5108 glaucoma implant shows promising results in . . .
    PolyActiva has announced promising results from its phase 2 clinical trial of PA5108, a novel glaucoma treatment implant The trial met key efficacy and safety end points, showing significant reductions in IOP over 26 weeks
  • PolyActiva reports positive phase 1b 2a data on biodegradable glaucoma . . .
    PolyActiva has released new findings from its phase 1b 2a clinical trial (LATA-CS102) evaluating the use of PA5108, its novel glaucoma treatment technology, in providing long-term drug delivery for glaucoma patients
  • PolyActiva Appoints Jerry St. Peter as CEO and Secures $25M . . . - BioSpace
    PolyActiva is a clinical-stage biopharmaceutical company developing novel drug delivery solutions to improve outcomes for patients with ocular conditions The company’s lead asset, PA5108, is a biodegradable ocular implant that delivers sustained latanoprost therapy to reduce intraocular pressure in glaucoma and ocular hypertension
  • PolyActiva raises $40m for glaucoma treatment tech
    The National Reconstruction Fund Corporation (NRFC) has committed $27 million to eye health-focused biotech PolyActiva as part of a $40 million Series C funding round, with the funds set to expand and consolidate its operations into a single facility for R D, analytics and manufacturing
  • PolyActiva secures $40 million AUD in Series C funding
    PolyActiva has secured AUD $40 million in Series C funding to support the continued clinical advancement of its lead ocular implant candidate, PA5108 PA5108 is a biodegradable, sustained-release ocular implant designed to deliver latanoprost for the reduction of intraocular pressure (IOP) in patients with ocular hypertension and glaucoma
  • PolyActivas PA5108 Implant Shows Promise | OBN
    PolyActiva has announced encouraging results from its Phase 2 clinical trial for the PA5108 glaucoma implant, a groundbreaking approach to long-term drug delivery for glaucoma patients The trial successfully met key efficacy and safety endpoints, demonstrating significant reductions in intraocular pressure (IOP) over 26 weeks
  • Pipeline - PolyActiva
    PolyActiva’s pipeline of ocular implants with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy for eye care professionals treating patients with a wide range of ocular diseases Micro implant Sustained drug release





中文字典-英文字典  2005-2009